BIIB Valuation - Is Biogen Inc Over or Undervalued?
Comprehensive analysis of Biogen Inc valuation metrics including P/E, P/B, P/S, and EV/EBITDA ratios
Current Stock Price
$191.82
Market Cap
$28.15B
Valuation Date
Feb 28, 2026
Valuation Verdict
Fairly Valued
Based on valuation multiples, BIIB appears reasonably priced relative to fundamentals. Metrics show balanced valuation.
Key Valuation Metrics
These four fundamental valuation ratios help determine if BIIB is trading at a fair price relative to its earnings, assets, revenue, and cash flow generation.
How to Interpret These Metrics
How BIIB Compares to Peers
What This Means for Investors
Balanced Valuation
Biogen Inc (BIIB) appears fairly valued based on current multiples. This balanced valuation suggests the stock is priced appropriately relative to its fundamentals. For investors, this means the stock may be suitable for those seeking exposure to Health Care without taking on significant valuation risk in either direction.
Bullish Considerations
- Reasonable price relative to book value
- Attractive price-to-sales multiple
- Favorable EV/EBITDA valuation
Bearish Considerations
Complete Your Analysis
Valuation is just one piece of the puzzle. Get the complete picture of BIIB with our comprehensive analysis tools.
Full Stock Analysis
Complete financials, charts, and metrics
Should I Buy BIIB?
AI-powered investment recommendation
Price Forecast
Future price targets and predictions
Analyst Ratings
Wall Street consensus and targets
Deep Valuation Analysis
DCF model and intrinsic value
Latest News
Breaking news and market sentiment
Frequently Asked Questions
What is BIIB's P/E ratio and what does it mean?
BIIB has a P/E (Price-to-Earnings) ratio of 21.82. This means investors are paying $21.82 for every $1 of annual earnings. A lower P/E generally suggests better value, but it's important to compare against industry peers and growth prospects. The market average P/E is typically 15-20x.
Is BIIB stock overvalued or undervalued?
Based on our analysis of key valuation metrics (P/E, P/B, P/S, EV/EBITDA), BIIB appears fairly valued. Based on valuation multiples, BIIB appears reasonably priced relative to fundamentals. Metrics show balanced valuation. However, valuation is just one factor to consider alongside growth prospects, competitive position, and market conditions.
What is a good P/E ratio for BIIB?
There's no single "good" P/E ratio as it varies by industry and growth stage. For Biogen Inc, compare the current P/E of 21.82 against: (1) Industry peers, (2) Historical average P/E for BIIB, (3) Expected earnings growth rate. High-growth companies often justify higher P/E ratios, while mature companies typically trade at lower multiples.
How do I use valuation ratios to make investment decisions?
Valuation ratios are screening tools, not buy/sell signals. Use them to: (1) Compare BIIB against competitors, (2) Identify potential over/undervaluation, (3) Understand what you're paying for earnings, assets, or sales. Combine valuation analysis with fundamental research, growth prospects, and technical analysis for comprehensive decision-making.
What is EV/EBITDA and why does it matter?
EV/EBITDA (Enterprise Value to EBITDA) is 11.66 for BIIB. This ratio is useful because it accounts for debt and excludes non-cash expenses, making it better for comparing companies with different capital structures. Lower EV/EBITDA generally indicates better value. It's particularly useful for comparing companies in capital-intensive industries.
Disclaimer: This valuation analysis is for informational and educational purposes only and should not be considered investment advice. Valuation metrics are just one factor in investment decisions. Always conduct comprehensive research and consult with a qualified financial advisor before making investment decisions. Past performance and current valuations do not guarantee future results.